Medicare Part D low-income subsidies alone are insufficient to improve the uptake and equitable use of high-cost, orally administered antimyeloma therapy.
Leah L. Zullig, PhD, MPH
Advertisement
Articles by Leah L. Zullig, PhD, MPH
Limited evidence from a literature review suggests that co-pay assistance was associated with improved treatment persistence/adherence across various diseases, with indirect evidence suggesting improvements in clinical outcomes.
Advertisement
Latest Updated Articles
- Association Between Low-Income Subsidies and Inequities in Orally Administered Antimyeloma Therapy Use
Published: May 16th 2023 | Updated:
- Impact of Co-pay Assistance on Patient, Clinical, and Economic Outcomes
Published: May 5th 2022 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis
2
FDA Approves Cemiplimab as First, Only Adjuvant Immunotherapy for High-Risk CSCC
3
How Medicaid Reforms Could Deepen State Coverage Gaps
4
Flow Cytometry Tool Could Improve Treatment Monitoring in MS
5
